TRCT
HAE icon

Tower Research Capital (TRC)’s Haemonetics HAE Stock Holding History

Tower Research Capital (TRC)’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$270K Buy
4,785
+1,515
+46% +$98.7K 0.01% 1382
2025
Q4 		$262K Sell
3,270
-911
-22% -$61.2K 0.01% 1231
2025
Q3 		$204K Sell
4,181
-4,523
-52% -$280K 0.01% 1442
2025
Q2 		$649K Buy
8,704
+6,687
+332% +$443K 0.02% 784
2025
Q1 		$128K Sell
2,017
-2,431
-55% -$165K ﹤0.01% 1636
2024
Q4 		$347K Buy
4,448
+1,399
+46% +$112K 0.01% 1302
2024
Q3 		$245K Sell
3,049
-8,039
-73% -$649K 0.01% 1425
2024
Q2 		$917K Buy
11,088
+9,992
+912% +$879K 0.02% 829
2024
Q1 		$93.5K Sell
1,096
-11,694
-91% -$918K ﹤0.01% 1864
2023
Q4 		$1.09M Buy
12,790
+10,917
+583% +$944K 0.01% 792
2023
Q3 		$168K Sell
1,873
-6,081
-76% -$543K 0.01% 1556
2023
Q2 		$677K Buy
7,954
+6,599
+487% +$558K 0.02% 767
2023
Q1 		$112K Sell
1,355
-324
-19% -$26.2K ﹤0.01% 1761
2022
Q4 		$132K Sell
1,679
-3,095
-65% -$249K 0.01% 1607
2022
Q3 		$354K Buy
4,774
+1,444
+43% +$104K 0.01% 1415
2022
Q2 		$217K Buy
3,330
+2,347
+239% +$139K ﹤0.01% 1708
2022
Q1 		$62K Sell
983
-6,824
-87% -$371K ﹤0.01% 2562
2021
Q4 		$415K Buy
7,807
+4,328
+124% +$264K 0.01% 1237
2021
Q3 		$246K Sell
3,479
-1,282
-27% -$80.9K 0.01% 1612
2021
Q2 		$317K Sell
4,761
-7,920
-62% -$560K 0.01% 1558
2021
Q1 		$1.41M Sell
12,681
-964
-7% -$119K 0.02% 606
2020
Q4 		$1.62M Sell
13,645
-14,146
-51% -$1.52M 0.05% 293
2020
Q3 		$2.42M Buy
27,791
+10,797
+64% +$944K 0.03% 285
2020
Q2 		$1.52M Buy
16,994
+16,055
+1,710% +$1.62M 0.06% 322
2020
Q1 		$94K Buy
939
+839
+839% +$91K 0.01% 1023
2019
Q4 		$11K Sell
100
-668
-87% -$80.8K ﹤0.01% 2281
2019
Q3 		$97K Sell
768
-37
-5% -$4.7K 0.01% 1366
2019
Q2 		$97K Sell
805
-2,695
-77% -$265K 0.01% 1194
2019
Q1 		$306K Buy
3,500
+3,414
+3,970% +$310K 0.02% 915
2018
Q4 		$9K Sell
86
-4,685
-98% -$492K ﹤0.01% 2537
2018
Q3 		$547K Sell
4,771
-195
-4% -$20.2K 0.04% 434
2018
Q2 		$445K Sell
4,966
-4,514
-48% -$381K 0.02% 697
2018
Q1 		$694K Buy
9,480
+8,803
+1,300% +$604K 0.06% 322
2017
Q4 		$39K Sell
677
-5,875
-90% -$309K 0.01% 1526
2017
Q3 		$294K Buy
6,552
+5,452
+496% +$227K 0.02% 500
2017
Q2 		$43K Buy
1,100
+1,098
+54,900% +$45.1K ﹤0.01% 821
2017
Q1 		$0 Sell
2
-931
-100% -$36.4K ﹤0.01% 3394
2016
Q4 		$38K Buy
+933
New +$35.2K ﹤0.01% 1609
2016
Q3 		– Sell
-4,574
Closed -$133K – 3950
2016
Q2 		$133K Buy
+4,574
New +$138K 0.01% 935
2016
Q1 		– Sell
-35
Closed -$1K – 4450
2015
Q4 		$1K Buy
+35
New +$1.14K ﹤0.01% 4079
2015
Q3 		– Sell
-5,239
Closed -$216K – 4310
2015
Q2 		$216K Sell
5,239
-371
-7% -$15.6K 0.02% 331
2015
Q1 		$252K Buy
5,610
+5,401
+2,584% +$226K 0.03% 314
2014
Q4 		$8K Sell
209
-6,816
-97% -$250K ﹤0.01% 2339
2014
Q3 		$245K Buy
7,025
+5,563
+381% +$199K 0.03% 454
2014
Q2 		$52K Sell
1,462
-1,092
-43% -$36.5K 0.01% 1266
2014
Q1 		$83K Buy
2,554
+2,096
+458% +$80.1K 0.01% 805
2013
Q4 		$19K Sell
458
-5,174
-92% -$213K ﹤0.01% 2383
2013
Q3 		$224K Buy
5,632
+3,932
+231% +$165K 0.02% 682
2013
Q2 		$70K Buy
+1,700
New +$68.8K 0.01% 699

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tower Research Capital (TRC)'s HAE Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Haemonetics (HAE) stake by 46% in Q1 2026, buying an estimated $98.7K and bringing the position to 4,785 shares worth $270K. The position accounts for 0.01% of the portfolio, ranked #1382.

Tower Research Capital (TRC) first reported a position in HAE in Q2 2013 and has held it in 49 quarters since. The position peaked at $2.42M in Q3 2020. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Tower Research Capital (TRC) held 4,785 shares of Haemonetics worth $270K as of Q1 2026.
  • Tower Research Capital (TRC) bought 1,515 Haemonetics shares in Q1 2026, an estimated $98.7K.
  • Haemonetics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1382 holding.
  • Tower Research Capital (TRC) first reported a position in Haemonetics in Q2 2013 and has held it in 49 quarters since.
  • Tower Research Capital (TRC)'s Haemonetics position peaked at $2.42M in Q3 2020.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.